How should a 58-year-old woman on dapagliflozin (Farxiga) and a diuretic who develops lightheadedness, intermittent shortness of breath, and heart rate swings from 33 to 105 bpm be managed?

Immediate Medication Adjustment and Cardiac Evaluation Required

This patient requires urgent discontinuation or dose reduction of her diuretic, immediate cardiac rhythm assessment with continuous monitoring, and careful evaluation of volume status before continuing dapagliflozin. The heart rate swings from 33 to 105 bpm with lightheadedness and shortness of breath suggest either symptomatic bradycardia with compensatory tachycardia, or underlying conduction disease unmasked by volume depletion from dual diuretic therapy.

Critical Management Steps

1. Stop or Reduce the Loop/Thiazide Diuretic Immediately

The combination of dapagliflozin (Farxiga) and a traditional diuretic creates additive volume depletion risk. Dapagliflozin causes volume depletion through osmotic diuresis, which is explicitly warned against in the FDA label, particularly in patients on loop diuretics 1. The label specifically states that patients on loop diuretics are at increased risk for volume depletion or hypotension, and volume status should be assessed before initiating therapy 1.

• Hold the traditional diuretic completely until volume status is reassessed
• Check orthostatic vital signs immediately
• Assess for signs of volume depletion: dry mucous membranes, decreased skin turgor, elevated BUN/creatinine ratio

2. Obtain Immediate ECG and Continuous Cardiac Monitoring

The heart rate of 33 bpm is critically bradycardic and requires urgent evaluation:

• 12-lead ECG to assess for:

  • High-degree AV block (second-degree type II or third-degree)
  • Sick sinus syndrome
  • Medication-induced bradycardia
  • Electrolyte abnormalities (hyperkalemia causing conduction delays)

• Continuous telemetry monitoring to capture rhythm during symptomatic episodes

• The heart rate variability (33-105 bpm) suggests either:

  • Tachy-brady syndrome (sick sinus syndrome)
  • Intermittent high-degree AV block with escape rhythms
  • Compensatory tachycardia during upright posture due to volume depletion

3. Check Electrolytes and Renal Function Urgently

Diuretics cause electrolyte depletion (potassium, magnesium) which predisposes to serious cardiac arrhythmias 2. The combination of two diuretic mechanisms markedly enhances this risk 2.

• Serum potassium, magnesium, sodium, BUN, creatinine
• Hypokalemia and hypomagnesemia can cause both bradyarrhythmias and tachyarrhythmias
• Hyperkalemia (less likely but possible with heart failure medications) can cause severe bradycardia
• Volume depletion can cause azotemia 2

4. Dapagliflozin Management Decision

Continue dapagliflozin at 10 mg daily ONLY if:

• Volume status is adequate after stopping the traditional diuretic
• No evidence of severe volume depletion (systolic BP >100 mmHg, no orthostatic hypotension)
• eGFR remains ≥25 mL/min/1.73m² 1
• Electrolytes are corrected

Temporarily hold dapagliflozin if:

• Symptomatic hypotension persists
• Evidence of severe volume depletion
• Acute kidney injury develops
• Patient cannot maintain oral intake 1

The FDA label explicitly states to "assess volume status and renal function" before initiating and to "monitor for signs and symptoms of hypotension" after starting therapy 1. Dapagliflozin has minimal direct effect on heart rate or conduction 3, 4, so the bradycardia is likely multifactorial from volume depletion, electrolyte abnormalities, or underlying conduction disease.

Specific Pitfalls to Avoid

Do Not Assume the Bradycardia is Medication-Related Without Evaluation

While beta-blockers and other heart failure medications can cause bradycardia, a heart rate of 33 bpm with symptoms requires structural/conduction system evaluation. Review ALL medications for rate-limiting agents.

Do Not Continue Dual Diuretic Therapy Without Clear Indication

The combination of SGLT2 inhibitor plus traditional diuretic significantly increases volume depletion risk 1. Guidelines recommend diuretics for fluid retention 5, but excessive diuresis causes hypotension, azotemia, and can precipitate arrhythmias 2. Most heart failure patients on dapagliflozin do NOT require aggressive traditional diuretic escalation 4.

Do Not Overlook Sick Sinus Syndrome or AV Block

The wide heart rate variability (33-105 bpm) is NOT normal medication effect. This pattern suggests:

• Tachy-brady syndrome: Periods of severe bradycardia alternating with tachycardia, often requiring pacemaker
• High-degree AV block: May require urgent pacing if symptomatic

Monitoring Plan After Stabilization

Once acute issues are addressed:

• Daily weights to guide diuretic dosing 5
• Electrolytes within 1 week of any medication adjustment 4
• If dapagliflozin is continued, it typically REDUCES the need for traditional diuretics 4, 6
• Consider cardiology referral if conduction abnormalities are identified

The key principle: Dapagliflozin provides benefit in heart failure 3, 4, 7, 1, but requires careful volume management and should not be combined with aggressive traditional diuretic therapy without clear volume overload. The current presentation suggests over-diuresis with possible unmasking of underlying conduction disease.